NCT05581407View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

August 3, 2023

Study Completion Date

October 23, 2023

Conditions
Influenza
Interventions
BIOLOGICAL

TETRALITE

LiteVax Adjuvanted Seasonal Influenza Vaccine

Trial Locations (1)

9000

CEVAC, University Hospital, Ghent

Sponsors

Lead Sponsor

LiteVax BV
All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

lead

LiteVax BV

INDUSTRY